LONDON, UNITED KINGDOM -- (Marketwired) -- 11/27/13 --
NuVasive, Inc. (NASDAQ: NUVA)
NuVasive, a global medical device company, will hold media tours to commemorate the official relocation and expansion of the Company's UK office at Elstree. The modern two-story, 7,500-square-foot facility adds office space, increases warehousing capabilities, and provides dedicated space for staffing, training and surgeon events.
Media are invited to join NuVasive for tours of the new facility. Interviews can be arranged with executives.
Wednesday, Dec. 4, 2013
8:30 a.m. GMT Tours of the NuVasive UK Facility
Nicole Collins / NuVasive Corporate Communications
+1 619-417-2117 (mobile)
Over the past ten years, NuVasive has strategically expanded into international markets to proliferate minimally disruptive spine surgery globally. Through the Company's unique culture of Absolute Responsiveness® to surgeon and hospital customers, NuVasive intends to improve more patient outcomes in the UK and around the world.
MEDIA OPPORTUNITIES: Interview opportunities are available with executives. Interviews, photo opportunities and b-roll will be available during the facility tour. RSVP to Nicole Collins at email@example.com. During the event, she can be reached at +44 2082-387-850.
PARKING: Parking is available onsite.
NuVasive is an innovative global medical device company that is changing spine surgery with minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is the 4th largest player in the $8.2 billion global spine market.
NuVasive offers a comprehensive spine portfolio of more than 80 unique products developed to improve spine surgery and patient outcomes. The Company's principal procedural solution is its Maximum Access Surgery, or MAS® platform for lateral spine fusion. MAS provides safe, reproducible, and clinically proven outcomes, and is a highly differentiated solution with fully integrated neuromonitoring, customizable exposure, and a broad offering of application-specific implants and fixation devices designed to address a variety of pathologies.
Having pioneered the lateral approach to spine fusion, NuVasive continues to be at the forefront of the spine industry's shift toward less invasive solutions. The Company's dedication to innovation continues to spawn game changing technology such as the PCM® motion preserving disc for the cervical spine, XLIF® Corpectomy for tumor and trauma, and Armada®, which treats adult degenerative scoliosis in a less invasive fashion. The Company has also developed procedural solutions that completely redefine and improve upon traditional procedures like TLIF, PLIF, Posterior Fixation, and ALIF. NuVasive's solutions are increasingly being adopted internationally, as the Company lays the groundwork to continue growing as a global business and to offer industry-leading, Absolutely Responsive customer service to surgeons world-wide. NuVasive is focused on becoming a $1 Billion Start-Up™; taking market share by maintaining a commitment to Superior Clinical Outcomes, Speed of Innovation®, and Absolute Responsiveness®.
NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to those risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
NuVasive Corporate Communications
+1 619-417-2117 (mobile)
Source: NuVasive, Inc.